Silo Pharma, Inc. (SILO)
↓ Download CSV- Sector Manufacturing
- Incorporated NV
- Fiscal year ends Dec 31
In fiscal 2025, Silo Pharma, Inc. reported revenue of $72.1K, up 0.0% from the prior year. The company ran a net loss, with a net margin of -5863.5% and a gross margin of 38.6%. It held $7.61M in total assets against $1.30M in total liabilities.
Key ratios (FY2025)
38.6%
Gross margin
-5937.0%
Operating margin
-5863.5%
Net margin
-67.0%
Return on equity
+0.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $72.1K | $72.1K | $72.1K | $72.1K | — | $40.9K | $40.6K | — | — | — |
| Cost of Revenue | $44.3K | $5.8K | $5.8K | $5.8K | $5.0K | — | — | — | — | — |
| Gross Profit | $27.8K | $66.3K | $66.3K | $66.3K | $66.3K | -$135.2K | $13.2K | — | — | — |
| Operating Income | -$4.28M | -$4.71M | -$3.86M | -$3.63M | -$2.74M | -$2.20M | -$930.4K | -$594.2K | -$490.9K | — |
| Net Income | -$4.23M | -$4.39M | -$3.70M | -$3.91M | $3.90M | -$3.04M | -$1.01M | -$969.5K | $356.5K | — |
| EPS (Diluted) | $-0.50 | $-1.19 | $-1.20 | — | $0.04 | $-0.05 | — | $-0.02 | $0.01 | — |
| Total Assets | $7.61M | $7.41M | $7.75M | $11.64M | $10.49M | $1.43M | $493.8K | $855.4K | $1.64M | — |
| Total Liabilities | $1.30M | $2.38M | $1.57M | $1.30M | $1.43M | $146.0K | $116.7K | — | — | — |
| Shareholders' Equity | $6.31M | $5.03M | $6.18M | $10.34M | $9.06M | $1.28M | -$22.9K | $407.4K | $1.20M | $846.5K |
| Cash & Equivalents | $4.75M | $3.91M | $3.52M | $11.37M | $9.84M | $1.13M | $111.8K | $336.7K | $294.6K | $579.2K |
| Operating Cash Flow | -$4.66M | -$3.83M | -$3.22M | -$3.50M | -$2.28M | -$1.16M | -$794.3K | $272.6K | -$284.6K | — |
| Shares Outstanding | 13.32M | 4.48M | 2.91M | 3.16M | 1.97M | 85.14M | 23.60M | 23.42M | 50.08M | — |